Business
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
Findings Presented at ATS 2022 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its
About this update from Veracyte, Inc.
[{"type":"text","content":"\nFindings Presented at ATS 2022\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on U.S. Preventive Services Task Force (USPSTF) screening criteria. The findings were presented today at the American Thoracic Society 2022 International Conference (ATS 2022), being held in San Francisco.\n\n“Our analysis showed that the nasal genomic classifier performed similarly well in patients across the spectrum of tobacco-related risk,\" said Carla R. Lamb, M.D., a pulmonary and critical care physician and Director of Interventional Pulmonary at Lahey Hospital & Medical Center who presented the study findings. “These findings suggest that the test can be reliably used in ever-smokers whose lung nodules were found incidentally, as well as through screening.”\n\nFor the study, researchers evaluated data from a subset of 291 current and former smokers with lung nodules who were part of the original clinical validation study for the Percepta Nasal Swab test. Among these individuals, 213 (73%) met USPSTF screening criteria (pack years ≥20, years since quit","length":2063,"tagName":"div"}]